Fulcrum Therapeutics Inc’s filing revealed that its 10% Owner RA CAPITAL MANAGEMENT, L.P. unloaded Company’s shares for reported $58.38 million on Dec 08 ’25. In the deal valued at $13.98 per share,4,175,139 shares were sold. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 6,053,960 shares worth roughly $78.7 million.
Then, RA Capital Healthcare Fund LP bought 4,175,139 shares, generating $54,235,056 in total proceeds.
Before that, Gould Robert J sold 15,000 shares. Fulcrum Therapeutics Inc shares valued at $165,495 were divested by the Director at a price of $11.03 per share. As a result of the transaction, Gould Robert J now holds 484,864 shares, worth roughly $6.3 million.
Truist initiated its Fulcrum Therapeutics Inc [FULC] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late July from “a Neutral” to “a Buy”. Leerink Partners also remained covering FULC and has increased its forecast on May 23, 2025 with a “an Outperform” recommendation from previously “Market perform” rating. Cantor Fitzgerald revised its rating on May 15, 2025. It rated FULC as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of FULC
On Friday, Fulcrum Therapeutics Inc [NASDAQ:FULC] saw its stock jump 1.56% to $13.0. Over the last five days, the stock has gained 46.07%. Fulcrum Therapeutics Inc shares have risen nearly 220.99% since the year began. Nevertheless, the stocks have risen 176.60% over the past one year. While a 52-week high of $15.74 was reached on 12/08/25, a 52-week low of $2.32 was recorded on 04/07/25.
Levels Of Support And Resistance For FULC Stock
The 24-hour chart illustrates a support level at 12.66, which if violated will result in even more drops to 12.31. On the upside, there is a resistance level at 13.27. A further resistance level may holdings at 13.53.
How much short interest is there in Fulcrum Therapeutics Inc?
A steep rise in short interest was recorded in Fulcrum Therapeutics Inc stocks on 2025-11-28, growing by 0.28 million shares to a total of 3.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 3.53 million shares. There was a rise of 7.39%, which implies that there is a positive sentiment for the stock.
